Natural Killer Cells in SARS-CoV-2-Vaccinated Subjects with Increased Effector Cytotoxic CD56dim Cells and Memory-Like CD57+NKG2C+CD56dim Cells
Background: The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity. Methods: Twenty healthy volunteers...
Saved in:
Published in | Frontiers in bioscience (Landmark. Print) Vol. 28; no. 7; p. 156 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
IMR Press
01.07.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity. Methods: Twenty healthy volunteers received three doses of Comirnaty (Pfizer Australia Pty Ltd.) and were evaluated 9 months after the second vaccination and 1 month after the booster dose. The exclusion criteria were the presence of adverse effects following the vaccination, a history of smoking, and heterologous immunization. The inclusion criteria were the absence of prior Coronavirus Disease (COVID)-19 history, the absence of adverse effects, and the absence of comorbidities. Specific phenotype and levels of CD107a and granzyme production by blood NK (natural killer) cells were analyzed after exposure to SARS-CoV-2 spike antigen (Wuhan, Alpha B.1.1.7, Delta B.1.617.2, and Omicron B1.1.529 variants), and related with anti-SARS-CoV-2 antibody production. Results: The booster dose caused early NK CD56dim subset activation and memory-like phenotype. Conclusions: We report the relevance of the innate immune response, especially NK cells, to SARS-CoV-2 vaccines to guarantee efficient protection against the infection following a booster dose. |
---|---|
AbstractList | Background: The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity. Methods: Twenty healthy volunteers received three doses of Comirnaty (Pfizer Australia Pty Ltd.) and were evaluated 9 months after the second vaccination and 1 month after the booster dose. The exclusion criteria were the presence of adverse effects following the vaccination, a history of smoking, and heterologous immunization. The inclusion criteria were the absence of prior Coronavirus Disease (COVID)-19 history, the absence of adverse effects, and the absence of comorbidities. Specific phenotype and levels of CD107a and granzyme production by blood NK (natural killer) cells were analyzed after exposure to SARS-CoV-2 spike antigen (Wuhan, Alpha B.1.1.7, Delta B.1.617.2, and Omicron B1.1.529 variants), and related with anti-SARS-CoV-2 antibody production. Results: The booster dose caused early NK CD56dim subset activation and memory-like phenotype. Conclusions: We report the relevance of the innate immune response, especially NK cells, to SARS-CoV-2 vaccines to guarantee efficient protection against the infection following a booster dose. The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity.BACKGROUNDThe infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity.Twenty healthy volunteers received three doses of Comirnaty (Pfizer Australia Pty Ltd.) and were evaluated 9 months after the second vaccination and 1 month after the booster dose. The exclusion criteria were the presence of adverse effects following the vaccination, a history of smoking, and heterologous immunization. The inclusion criteria were the absence of prior Coronavirus Disease (COVID)-19 history, the absence of adverse effects, and the absence of comorbidities. Specific phenotype and levels of CD107a and granzyme production by blood NK (natural killer) cells were analyzed after exposure to SARS-CoV-2 spike antigen (Wuhan, Alpha B.1.1.7, Delta B.1.617.2, and Omicron B1.1.529 variants), and related with anti-SARS-CoV-2 antibody production.METHODSTwenty healthy volunteers received three doses of Comirnaty (Pfizer Australia Pty Ltd.) and were evaluated 9 months after the second vaccination and 1 month after the booster dose. The exclusion criteria were the presence of adverse effects following the vaccination, a history of smoking, and heterologous immunization. The inclusion criteria were the absence of prior Coronavirus Disease (COVID)-19 history, the absence of adverse effects, and the absence of comorbidities. Specific phenotype and levels of CD107a and granzyme production by blood NK (natural killer) cells were analyzed after exposure to SARS-CoV-2 spike antigen (Wuhan, Alpha B.1.1.7, Delta B.1.617.2, and Omicron B1.1.529 variants), and related with anti-SARS-CoV-2 antibody production.The booster dose caused early NK CD56dim subset activation and memory-like phenotype.RESULTSThe booster dose caused early NK CD56dim subset activation and memory-like phenotype.We report the relevance of the innate immune response, especially NK cells, to SARS-CoV-2 vaccines to guarantee efficient protection against the infection following a booster dose.CONCLUSIONSWe report the relevance of the innate immune response, especially NK cells, to SARS-CoV-2 vaccines to guarantee efficient protection against the infection following a booster dose. |
Author | Contoli, Marco Zauli, Giorgio Gentili, Valentina Rizzo, Sabrina Casciano, Fabio Bortolotti, Daria Schiuma, Giovanna Beltrami, Silvia Papi, Alberto Morandi, Luca Rizzo, Roberta |
Author_xml | – sequence: 1 givenname: Valentina orcidid: 0000-0003-4572-5497 surname: Gentili fullname: Gentili, Valentina – sequence: 2 givenname: Daria orcidid: 0000-0003-4496-9561 surname: Bortolotti fullname: Bortolotti, Daria – sequence: 3 givenname: Luca orcidid: 0000-0001-7264-206X surname: Morandi fullname: Morandi, Luca – sequence: 4 givenname: Sabrina orcidid: 0000-0002-9246-136X surname: Rizzo fullname: Rizzo, Sabrina – sequence: 5 givenname: Giovanna orcidid: 0000-0003-4652-5550 surname: Schiuma fullname: Schiuma, Giovanna – sequence: 6 givenname: Silvia orcidid: 0000-0002-5923-9265 surname: Beltrami fullname: Beltrami, Silvia – sequence: 7 givenname: Fabio orcidid: 0000-0002-6431-3335 surname: Casciano fullname: Casciano, Fabio – sequence: 8 givenname: Alberto orcidid: 0000-0002-6924-4500 surname: Papi fullname: Papi, Alberto – sequence: 9 givenname: Marco orcidid: 0000-0002-2731-5809 surname: Contoli fullname: Contoli, Marco – sequence: 10 givenname: Giorgio orcidid: 0000-0002-3750-8698 surname: Zauli fullname: Zauli, Giorgio – sequence: 11 givenname: Roberta orcidid: 0000-0001-9507-9126 surname: Rizzo fullname: Rizzo, Roberta |
BookMark | eNp1kU9v1DAQxSPUSpS2R-45IlUp_m_nWIW2rLoUiYVeLcceg5dsXGyvYD8FXxnTLSCQOM3o-TfvaTzPmoM5ztA0zzE6pxgp-nJ97seJKCQxF0-aIyKF6oTo1cGvXiL8tDnNeY0QIj3GPVdHzfdbU7bJTO1NmCZI7QDTlNswt6uLd6tuiHcd6e6MtWE2BVy72o5rsCW3X0P51C5mm8Dkql96X-VY53cllvgt2HZ4xYULm0dHM7v2DWxi2nXL8Bl-vsqz25trMpz9BZ40h95MGU4f63Hz4ery_fC6W769XgwXy85SyUvHHbOKjKOihDlcdwHlhOu9AQqu_gYCDhQb1fPReOqYB8SslNJ44gA4o8fNYu_rolnr-xQ2Ju10NEE_CDF91CaVYCfQbGSkRvmx55SZXo01zyIpkGCYYUqr14u9132KX7aQi96EbOs2Zoa4zZooxoRUiouKdnvUpphzAv87GiP9cEe91n_uWHn6D29DMSXEuSQTpv9M_QAq8KEt |
CitedBy_id | crossref_primary_10_31083_j_fbl2903107 crossref_primary_10_1186_s12985_024_02287_0 |
Cites_doi | 10.1001/jama.2021.7563 10.1038/s41467-023-35862-0 10.3390/cells9091975 10.1016/j.jim.2004.08.008 10.1038/s41423-020-0402-2 10.1038/s41586-021-03738-2 10.1111/j.1365-2567.2008.03027.x 10.1016/j.cellimm.2021.104454 10.1046/j.1365-2567.1999.00738.x 10.1056/NEJMoa2115481 10.1084/jem.20122571 10.1038/s41423-020-0483-y 10.1016/j.chom.2020.04.009 10.3390/immuno1030021 10.3390/v9120367 10.1038/ni1395 10.1016/j.ijid.2022.06.020 10.3389/fimmu.2020.01441 10.1016/S2666-5247(21)00069-0 10.1056/NEJMoa2034577 10.1089/152581600419116 10.1182/blood-2010-04-282301 10.1126/sciimmunol.abd6832 10.1016/B978-0-12-370454-2.00015-6 10.3389/fimmu.2022.888313 10.3390/microorganisms10030501 10.1038/s41577-021-00526-x 10.1038/s41591-020-0944-y 10.3389/fimmu.2022.798813 10.1038/cdd.2015.3 10.1111/j.1365-2567.2009.03123.x 10.1016/j.coi.2006.05.002 |
ContentType | Journal Article |
Copyright | 2023 The Author(s). Published by IMR Press. |
Copyright_xml | – notice: 2023 The Author(s). Published by IMR Press. |
DBID | AAYXX CITATION 7X8 DOA |
DOI | 10.31083/j.fbl2807156 |
DatabaseName | CrossRef MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2768-6698 |
ExternalDocumentID | oai_doaj_org_article_4b422bbfb9534a98b111c07606414133 10_31083_j_fbl2807156 |
GroupedDBID | 3IV 53G AAFWJ AAYXX AFPKN ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ 7X8 |
ID | FETCH-LOGICAL-c375t-5d4c82bb8324d1119e8d6d9fae3ed0830e5e31a895baf3d4fe04c777af2dee543 |
IEDL.DBID | DOA |
ISSN | 2768-6701 2768-6698 |
IngestDate | Wed Aug 27 01:20:06 EDT 2025 Fri Jul 11 07:30:08 EDT 2025 Thu Apr 24 23:02:25 EDT 2025 Tue Jul 01 01:37:53 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c375t-5d4c82bb8324d1119e8d6d9fae3ed0830e5e31a895baf3d4fe04c777af2dee543 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-9246-136X 0000-0002-6431-3335 0000-0003-4572-5497 0000-0003-4652-5550 0000-0003-4496-9561 0000-0001-9507-9126 0000-0002-6924-4500 0000-0001-7264-206X 0000-0002-5923-9265 0000-0002-2731-5809 0000-0002-3750-8698 |
OpenAccessLink | https://doaj.org/article/4b422bbfb9534a98b111c07606414133 |
PQID | 2844678856 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_4b422bbfb9534a98b111c07606414133 proquest_miscellaneous_2844678856 crossref_primary_10_31083_j_fbl2807156 crossref_citationtrail_10_31083_j_fbl2807156 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-07-01 |
PublicationDateYYYYMMDD | 2023-07-01 |
PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Frontiers in bioscience (Landmark. Print) |
PublicationYear | 2023 |
Publisher | IMR Press |
Publisher_xml | – name: IMR Press |
References | ref13 ref12 ref15 ref14 ref31 ref30 ref11 ref10 ref32 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref2 doi: 10.1001/jama.2021.7563 – ident: ref21 doi: 10.1038/s41467-023-35862-0 – ident: ref32 doi: 10.3390/cells9091975 – ident: ref31 doi: 10.1016/j.jim.2004.08.008 – ident: ref12 doi: 10.1038/s41423-020-0402-2 – ident: ref3 doi: 10.1038/s41586-021-03738-2 – ident: ref10 doi: 10.1111/j.1365-2567.2008.03027.x – ident: ref29 doi: 10.1016/j.cellimm.2021.104454 – ident: ref30 doi: 10.1046/j.1365-2567.1999.00738.x – ident: ref4 doi: 10.1056/NEJMoa2115481 – ident: ref27 doi: 10.1084/jem.20122571 – ident: ref16 doi: 10.1038/s41423-020-0483-y – ident: ref13 doi: 10.1016/j.chom.2020.04.009 – ident: ref25 doi: 10.3390/immuno1030021 – ident: ref24 doi: 10.3390/v9120367 – ident: ref28 doi: 10.1038/ni1395 – ident: ref20 doi: 10.1016/j.ijid.2022.06.020 – ident: ref11 doi: 10.3389/fimmu.2020.01441 – ident: ref1 doi: 10.1016/S2666-5247(21)00069-0 – ident: ref17 doi: 10.1056/NEJMoa2034577 – ident: ref19 doi: 10.1089/152581600419116 – ident: ref26 doi: 10.1182/blood-2010-04-282301 – ident: ref14 doi: 10.1126/sciimmunol.abd6832 – ident: ref8 doi: 10.1016/B978-0-12-370454-2.00015-6 – ident: ref9 doi: 10.3389/fimmu.2022.888313 – ident: ref23 doi: 10.3390/microorganisms10030501 – ident: ref22 doi: 10.1038/s41577-021-00526-x – ident: ref15 doi: 10.1038/s41591-020-0944-y – ident: ref18 doi: 10.3389/fimmu.2022.798813 – ident: ref6 doi: 10.1038/cdd.2015.3 – ident: ref7 doi: 10.1111/j.1365-2567.2009.03123.x – ident: ref5 doi: 10.1016/j.coi.2006.05.002 |
SSID | ssj0002911958 |
Score | 2.2528272 |
Snippet | Background: The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown... The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether... |
SourceID | doaj proquest crossref |
SourceType | Open Website Aggregation Database Enrichment Source Index Database |
StartPage | 156 |
SubjectTerms | innate response nk cell sars-cov-2 vaccine |
Title | Natural Killer Cells in SARS-CoV-2-Vaccinated Subjects with Increased Effector Cytotoxic CD56dim Cells and Memory-Like CD57+NKG2C+CD56dim Cells |
URI | https://www.proquest.com/docview/2844678856 https://doaj.org/article/4b422bbfb9534a98b111c07606414133 |
Volume | 28 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxRBEG4kIHgRn7i-aEG8aJudfk4f42oMxuzBmJDb0E-YuM6IOwH3V_iXreqZxAURL15nah5UVVdVd1d_HyHPveYymZyZ8BVnUjvOLJ8LpmwMkptcZ4HnnY-W-uBEfjhTZ1tUX9gTNsIDj4rblV5y7n32VgnpbO1hcAbcTtKyggBccD4h521NpjAGc4tQZoWODuppps28GgE2oZqpxe756-xXiANTIXH1VkIquP1_hOWSa_ZvkZtTkUj3xp-7Ta6l7g65PtJGbu6Sn0tX0DLoYTnIRxdptVrTtqPHe5-O2aI_ZZyduhDaDgrJSCE24GLLmuKaK4WAgH3ocH0ELu7h-c3QD_2PNtDFW6Vj-3V6o-siPcJO3A372H5JeNe8XB6-x7XVbcF75GT_3efFAZuIFVgQRg1MRRlqUCqMZhlBnzbVUUebXRIpgn7mSSVRudoq78BWMqe5DMYYl3lMSUlxn-x0fZceEKpjMM6KmCwPMnPjoIJL0ULeU5XnTs3Iq0vtNmFCHUfyi1UDs49iDJh-_DbGjLy4Ev82wm38TfANmupKCFGyywXwnWbyneZfvjMjzy4N3cCowq0S16X-Yt1A0oYMUtdKP_wfH3pEbiBN_djm-5jsDN8v0hMoZgb_tPjtL9XK7Bs |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+Killer+Cells+in+SARS-CoV-2-Vaccinated+Subjects+with+Increased+Effector+Cytotoxic+CD56dim+Cells+and+Memory-Like+CD57%2BNKG2C%2BCD56dim+Cells&rft.jtitle=Frontiers+in+bioscience+%28Landmark.+Print%29&rft.au=Valentina+Gentili&rft.au=Daria+Bortolotti&rft.au=Luca+Morandi&rft.au=Sabrina+Rizzo&rft.date=2023-07-01&rft.pub=IMR+Press&rft.issn=2768-6701&rft.volume=28&rft.issue=7&rft.spage=156&rft_id=info:doi/10.31083%2Fj.fbl2807156&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_4b422bbfb9534a98b111c07606414133 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2768-6701&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2768-6701&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2768-6701&client=summon |